financetom
Business
financetom
/
Business
/
Ardent Health Q3 Swings to Loss, Revenue Rises; 2025 EPS Guidance Cut; Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ardent Health Q3 Swings to Loss, Revenue Rises; 2025 EPS Guidance Cut; Shares Fall After Hours
Nov 12, 2025 2:26 PM

05:12 PM EST, 11/12/2025 (MT Newswires) -- Ardent Health ( ARDT ) reported a Q3 net loss late Wednesday of $0.17 per diluted share, compared with earnings of $0.19 a year earlier.

Analysts polled by FactSet expected earnings of $0.42.

Revenue in the three months ended Sept. 30 rose to $1.58 billion from $1.45 billion a year earlier.

Analysts surveyed by FactSet expected $1.55 billion.

The company slashed full-year earnings guidance to the range of $0.85 to $1.03 from its previous forecast of $1.73 to $2.01. Analysts polled by FactSet expect GAAP earnings of $1.83.

The company affirmed full-year revenue guidance at $6.2 billion to $6.45 billion. Analysts polled by FactSet expect $6.35 billion.

Ardent Health ( ARDT ) shares fell 25% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canada's East Side Games Q3 revenue misses expectations
Canada's East Side Games Q3 revenue misses expectations
Nov 13, 2025
Overview * East Side Games ( EAGRF ) Q3 revenue decreased 6% yr/yr, missing analyst expectations * EBITDA turned negative due to investments in new game launches and marketing * Company repurchased 147,000 shares, reflecting commitment to shareholder value Outlook * East Side Games ( EAGRF ) expects Q4 to be driven by seasonal events and new features * Company...
Aptose Biosciences Q3 net loss narrows
Aptose Biosciences Q3 net loss narrows
Nov 13, 2025
Overview * Aptose reports Q3 net loss of $5.1 mln, down from $7.0 mln last year * Research and development expenses decreased due to reduced clinical and manufacturing activity Outlook * Company did not provide specific financial guidance Result Drivers * R&D: Research and development expenses decreased by $2.5 million to $2.2 million for the quarter ended September 30 Key...
Canada's DPM Metals beats Q3 adjusted EPS estimates
Canada's DPM Metals beats Q3 adjusted EPS estimates
Nov 13, 2025
Overview * DPM Metals ( DPMLF ) Q3 adjusted EPS and adjusted EBITDA beat analysts' estimates * Revenue rose 82% yr/yr to $267.4 mln * Company completed acquisition of Adriatic Metals, integrating Vareš operation into portfolio Outlook * DPM expects higher Vareš production in 2026 than previously anticipated * Čoka Rakita feasibility study on track for completion by year-end 2025...
Canada's CES Q3 revenue beats expectations driven by favorable product mix 
Canada's CES Q3 revenue beats expectations driven by favorable product mix 
Nov 13, 2025
Overview * CES Q3 2025 revenue beats analyst expectations, driven by favorable product mix * Record Adjusted EBITDAC of C$103.3 mln at 16.6% margin for Q3 2025 * Company returns C$45.4 mln to shareholders through dividends and share repurchases Outlook * CES expects 2025 capital expenditures to be C$80 mln, rising to C$85-C$90 mln in 2026 * Company sees constructive...
Copyright 2023-2026 - www.financetom.com All Rights Reserved